All In Biotech

Drug Trial Radar · NCT07503587

Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis

A Randomised, Double-blind, Placebo-controlled Parallel Group Phase III Clinical Study Evaluating the Efficacy and Safety of HSK44459 Tablets in Subjects With Progressive Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 378 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

378

Planned (sponsor's estimate)

Start

Apr 5, 2026

Primary completion

Dec 30, 2028

Study completion Mar 1, 2029

Sponsor

Sponsor type
Industry
First posted
Mar 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with PPF . The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.

Conditions

  • Progressive Pulmonary Fibrosis

Interventions

  • HSK44459Drug

    HSK44459 taken orally twice daily in the morning and in the evening for 52weeks.

  • PlaceboDrug

    Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change from baseline in forced vital capacity (FVC) at week 52Time frame: day 1 and week 52

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.